Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  IQVIA Holdings Inc.    IQV


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

IQVIA :'s eCOA Solution Receives 2020 Fierce Innovation Award

share with twitter share with LinkedIn share with facebook
09/14/2020 | 08:11am EDT

IQVIA™ (NYSE: IQV) today announced that its electronic Clinical Outcome Assessment (eCOA) solution, an advanced-study build and execution platform that optimizes real-time, direct-from-patient data collection, has been selected as the winner of the Fierce Innovation Awards – Life Sciences Edition 2020 in the Digital Health Solutions category. The Fierce Innovation Awards is a peer-reviewed awards program produced by Questex, the publisher of Fierce Biotech and Fierce Pharma.

“We are honored to receive this prestigious award, which showcases outstanding innovation that is driving improvements and transforming the industry,” said Eric Hodgins, senior vice president, Real World Technology Solutions at IQVIA. “By building in the scientific expertise and intelligence needed within the eCOA technology and incorporating a truly agile development process, we are dramatically reducing the time to develop these tools while improving data quality and enhancing the patient experience.”

IQVIA eCOA is built on a highly secure, scalable SaaS platform that enables faster, flexible startup in clinical research and real world studies. IQVIA’s eCOA platform cuts up to three months from the industry standard eCOA development timeline while simultaneously improving the design through artificial intelligence-enabled design tools. This allows sponsors to launch trials faster and ensures the assessments will capture the right real-time insights to inform trial progress and demonstrate results.

IQVIA eCOA has a variety of capabilities that enhance the user experience and lead to time reductions, including a global library of pre-built assessments, which provides on-demand access to validated tools that can instantly be deployed. Currently, there are more than 850 assessments pre-configured in the library across a multitude of therapeutic areas.

The Fierce Innovation Awards go to companies that demonstrate innovative technologies and services with the potential to make the greatest impact for the life sciences industry. The awards program’s applications are reviewed by an exclusive panel of executives from major biotech and pharma companies. All honorees are evaluated based on effectiveness, technical innovation, competitive advantage, financial impact and true innovation.

Winners were announced in the 2020 Innovation Report published by Fierce Healthcare in September 2020.

For more information on IQVIA eCOA, please visit https://www.iqvia.com/solutions/technologies/patient-engagement/ecoa.


IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about IQVIA HOLDINGS INC.
07:18aIQVIA : 3Q Earnings Snapshot
07:07aIQVIA HOLDINGS INC. : Results of Operations and Financial Condition, Financial S..
07:03aIQVIA : Reports Third-Quarter 2020 Results, Raises Full-Year 2020 Guidance and P..
10/15IQVIA HOLDINGS INC. : quaterly earnings release
10/12IQVIA : Joins FDA to Advance COVID-19 Understanding at Community Level through C..
10/07IQVIA : to Announce Third-Quarter Results on October 20, 2020
10/06IQVIA INSTITUTE FOR HUMAN DATA SCIEN : Biosimilars Reach Inflection Point &ndash..
10/05IQVIA : and Medvarsity Collaborate to Provide Flexible Medical Training Solution..
09/14IQVIA : 's eCOA Solution Receives 2020 Fierce Innovation Award
09/01FACTBOX : AstraZeneca's potential coronavirus vaccine
More news
Financials (USD)
Sales 2020 11 183 M - -
Net income 2020 298 M - -
Net Debt 2020 10 359 M - -
P/E ratio 2020 107x
Yield 2020 -
Capitalization 31 378 M 31 378 M -
EV / Sales 2020 3,73x
EV / Sales 2021 3,31x
Nbr of Employees 67 000
Free-Float 74,5%
Duration : Period :
IQVIA Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IQVIA HOLDINGS INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 22
Average target price 184,11 $
Last Close Price 164,05 $
Spread / Highest target 25,0%
Spread / Average Target 12,2%
Spread / Lowest Target -15,9%
EPS Revisions
Ari Bousbib Chairman, President & Chief Executive Officer
James Grant Berkshire Senior Vice President-Business Operations
Ronald Earl Bruehlman Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
John M. Leonard Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP AG64.78%47 531
SEAGEN INC.73.48%34 490
CELLTRION, INC.35.64%29 974
MODERNA, INC.262.78%28 000
IMMUNOMEDICS, INC.314.04%20 266